Treatment of Latent Autoimmune Diabetes of the Adult

• Status: Completed
• Trial end date: 2018-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to clarify whether patients classified as Latent autoimmune diabetes of the adult (LADA) benefit from early treatment with insulin added to per oral treatment and lifestyle measures.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Norwegian University of Science and Technology
• Treatments: Insulin; Insulin, Globin Zinc; Insulin, Isophane; Isophane insulin, beef; Isophane Insulin, Human; Metformin; Repaglinide; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Diabetes diagnosed during 0-3 years before entering the study.

• Age > or equal to 30 years < or equal to 75 years

• anti-GAD positivity

• fasting C-peptide > or equal to 0,3 ng/ml

• no need for insulin treatment by clinical judgement for at least 3 months following the diagnosis of diabetes.

• HbA1c > 15 % above the upper limit of normal

Exclusion Criteria:

• Renal insufficiency (plasma creatinine > 150 mol/L)

• Severe retinopathy (proliferative or pre-proliferative)

• Severe cardiac disease (NYHA III-IV)

• Chronic severe illness judged by the investigator

• Females of reproductive age who wish to become pregnant during the study